Surmodics (SRDX) Stock Forecast, Price Target & Predictions
SRDX Stock Forecast
Surmodics stock forecast is as follows: an average price target of $39.50 (represents a 0.36% upside from SRDX’s last price of $39.36) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
SRDX Price Target
The average price target for Surmodics (SRDX) is $39.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $43.00 to $36.00. This represents a potential 0.36% upside from SRDX's last price of $39.36.
SRDX Analyst Ratings
According to 2 Wall Street analysts, Surmodics's rating consensus is 'Buy'. The analyst rating breakdown for SRDX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Surmodics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 29, 2024 | Brooks O'Neil | Lake Street | $43.00 | $42.07 | 2.21% | 9.25% |
| Jun 13, 2023 | Downgrades Stock | Needham | $36.00 | $26.34 | 36.65% | -8.54% |
| Apr 28, 2022 | - | Needham | $46.00 | $40.05 | 14.86% | 16.87% |
The latest Surmodics stock forecast, released on May 29, 2024 by Brooks O'Neil from Lake Street, set a price target of $43.00, which represents a 2.21% increase from the stock price at the time of the forecast ($42.07), and a 9.25% increase from SRDX last price ($39.36).
Surmodics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $43.00 |
| Last Closing Price | $39.36 | $39.36 | $39.36 |
| Upside/Downside | -100.00% | -100.00% | 9.25% |
In the current month, the average price target of Surmodics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Surmodics's last price of $39.36. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 30, 2024 | Needham | Underperform | Underperform | Hold |
| May 30, 2024 | Sidoti & Co. | Buy | Buy | Hold |
| May 29, 2024 | Lake Street | - | Hold | Downgrade |
| Feb 13, 2023 | Needham | Buy | Hold | Downgrade |
| Apr 28, 2022 | Needham | Buy | Buy | Hold |
Surmodics's last stock rating was published by Needham on May 30, 2024. The company gave SRDX a "Underperform" rating, the same as its previous rate.
Surmodics Financial Forecast
Surmodics Revenue Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $30.55M | $27.97M | $52.48M | $27.20M | $24.93M | $25.99M | - | $26.11M | $23.00M | $23.97M | $23.87M | $34.99M | $22.30M | $22.54M | $26.88M | $22.82M | $22.62M | $30.82M | $24.34M |
| Avg Forecast | $34.34M | $34.49M | $36.27M | $35.01M | $35.22M | $34.37M | $35.03M | $33.13M | $30.40M | $29.95M | $28.84M | $29.64M | $26.27M | $26.18M | $25.86M | $24.23M | $24.09M | $25.19M | $23.97M | $23.71M | $23.06M | $23.31M | $32.96M | $22.55M | $20.77M | $23.75M | $20.84M | $22.08M | $28.36M | $22.29M |
| High Forecast | $34.68M | $34.83M | $36.63M | $35.35M | $35.56M | $34.71M | $35.38M | $33.46M | $30.70M | $30.25M | $29.13M | $29.65M | $26.50M | $26.44M | $26.12M | $24.47M | $24.33M | $25.19M | $24.15M | $23.88M | $23.24M | $23.49M | $33.20M | $22.72M | $20.92M | $23.93M | $21.00M | $22.24M | $28.57M | $22.46M |
| Low Forecast | $34.13M | $34.27M | $36.05M | $34.79M | $35.00M | $34.15M | $34.82M | $32.92M | $30.21M | $29.77M | $28.66M | $29.62M | $25.99M | $26.02M | $25.70M | $24.07M | $23.94M | $25.19M | $23.66M | $23.40M | $22.76M | $23.01M | $32.52M | $22.25M | $20.49M | $23.44M | $20.57M | $21.79M | $27.98M | $22.00M |
| # Analysts | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.06% | 2.00% | 1.05% | 1.03% | 1.08% | - | 1.09% | 0.97% | 1.04% | 1.02% | 1.06% | 0.99% | 1.09% | 1.13% | 1.09% | 1.02% | 1.09% | 1.09% |
Surmodics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $28.84M, with a low forecast of $28.66M, and a high forecast of $29.13M. SRDX's average Quarter revenue forecast represents a -5.59% decrease compared to the company's last Quarter revenue of $30.55M (Dec 23).
Surmodics EBITDA Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-322.00K | $-293.00K | $21.41M | $-1.93M | $-5.11M | $-5.65M | - | $-2.58M | $270.00K | $1.98M | $-608.00K | $11.49M | $1.75M | $-171.00K | $3.03M | $1.34M | $1.74M | $6.01M | $3.13M |
| Avg Forecast | $1.40M | $1.41M | $1.48M | $1.43M | $1.44M | $1.40M | $1.43M | $1.35M | $1.24M | $1.22M | $-4.18M | $1.21M | $1.07M | $1.07M | $-3.80M | $988.67K | $3.13M | $1.03M | $-3.45M | $384.10K | $2.85M | $-304.00K | $11.67M | $3.50M | $-157.76K | $2.71M | $2.85M | $4.12M | $6.01M | $3.13M |
| High Forecast | $1.42M | $1.42M | $1.49M | $1.44M | $1.45M | $1.42M | $1.44M | $1.37M | $1.25M | $1.23M | $-3.34M | $1.21M | $1.08M | $1.08M | $-3.04M | $998.43K | $3.76M | $1.03M | $-2.76M | $460.92K | $3.42M | $-243.20K | $14.01M | $4.20M | $-126.21K | $3.25M | $3.42M | $4.94M | $7.21M | $3.76M |
| Low Forecast | $1.39M | $1.40M | $1.47M | $1.42M | $1.43M | $1.39M | $1.42M | $1.34M | $1.23M | $1.21M | $-5.02M | $1.21M | $1.06M | $1.06M | $-4.56M | $982.49K | $2.51M | $1.03M | $-4.14M | $307.28K | $2.28M | $-364.80K | $9.34M | $2.80M | $-189.31K | $2.17M | $2.28M | $3.29M | $4.81M | $2.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -0.27% | -0.27% | 20.04% | 0.51% | -5.17% | -1.80% | - | 0.75% | 0.70% | 0.69% | 2.00% | 0.98% | 0.50% | 1.08% | 1.12% | 0.47% | 0.42% | 1.00% | 1.00% |
4 analysts predict SRDX's average Quarter EBITDA for Sep 23 to be $1.07M, with a high of $1.08M and a low of $1.06M. This is -94.99% lower than Surmodics's previous annual EBITDA (Jun 23) of $21.41M.
Surmodics Net Income Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-786.00K | $6.69M | $33.95M | $-7.73M | $-7.84M | $-14.73M | - | $-4.08M | $-4.22M | $-289.00K | $-3.29M | $8.09M | $62.00 | $-2.95M | $2.46M | $1.46M | $148.00K | $3.55M | $1.47M |
| Avg Forecast | $-1.21M | $-1.21M | $-1.27M | $-1.23M | $-141.70K | $-472.33K | $-1.28M | $-1.65M | $-4.16M | $-4.78M | $-6.68M | $-4.61M | $2.23M | $-6.52M | $-6.08M | $-8.89M | $-457.77K | $-5.71M | $-5.52M | $-4.00M | $-416.16K | $-1.64M | $8.22M | $123.00 | $-2.72M | $2.20M | $3.11M | $349.65K | $3.55M | $1.47M |
| High Forecast | $-1.20M | $-1.20M | $-1.26M | $-1.22M | $-140.55K | $-468.49K | $-1.26M | $-1.64M | $-4.12M | $-4.74M | $-5.35M | $-4.57M | $2.60M | $-6.47M | $-4.86M | $-8.82M | $-366.22K | $-5.71M | $-4.42M | $-3.20M | $-332.93K | $-1.31M | $9.86M | $148.00 | $-2.17M | $2.64M | $3.73M | $419.58K | $4.26M | $1.76M |
| Low Forecast | $-1.22M | $-1.23M | $-1.29M | $-1.25M | $-143.52K | $-478.39K | $-1.29M | $-1.67M | $-4.21M | $-4.84M | $-8.02M | $-4.66M | $1.98M | $-6.60M | $-7.29M | $-9.01M | $-549.33K | $-5.71M | $-6.63M | $-4.80M | $-499.39K | $-1.97M | $6.57M | $99.00 | $-3.26M | $1.76M | $2.49M | $279.72K | $2.84M | $1.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.17% | 3.00% | -5.21% | 1.27% | 0.88% | 32.17% | - | 0.74% | 1.06% | 0.69% | 2.00% | 0.98% | 0.50% | 1.08% | 1.12% | 0.47% | 0.42% | 1.00% | 1.00% |
Surmodics's average Quarter net income forecast for Dec 23 is $-4.61M, with a range of $-4.66M to $-4.57M. SRDX's average Quarter net income forecast represents a -168.80% decrease compared to the company's last Quarter net income of $6.69M (Sep 23).
Surmodics SG&A Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $12.54M | $12.81M | $12.87M | $12.97M | $13.24M | $13.78M | - | $11.11M | $9.19M | $7.86M | $7.88M | $7.91M | $7.02M | $7.30M | $7.42M | $6.73M | $6.94M | $7.19M | $5.94M |
| Avg Forecast | $11.62M | $11.67M | $12.27M | $11.84M | $11.91M | $11.63M | $11.85M | $11.21M | $10.28M | $10.13M | $18.19M | $10.03M | $8.89M | $8.86M | $16.54M | $8.20M | $12.45M | $8.52M | $15.04M | $13.08M | $11.32M | $3.94M | $8.03M | $14.05M | $6.73M | $6.64M | $14.32M | $16.40M | $7.19M | $5.94M |
| High Forecast | $11.73M | $11.78M | $12.39M | $11.96M | $12.03M | $11.74M | $11.97M | $11.32M | $10.38M | $10.23M | $21.83M | $10.03M | $8.97M | $8.94M | $19.85M | $8.28M | $14.94M | $8.52M | $18.04M | $15.69M | $13.59M | $4.73M | $9.64M | $16.86M | $8.08M | $7.96M | $17.19M | $19.68M | $8.62M | $7.13M |
| Low Forecast | $11.55M | $11.59M | $12.19M | $11.77M | $11.84M | $11.55M | $11.78M | $11.14M | $10.22M | $10.07M | $14.55M | $10.02M | $8.79M | $8.80M | $13.23M | $8.14M | $9.96M | $8.52M | $12.03M | $10.46M | $9.06M | $3.15M | $6.43M | $11.24M | $5.39M | $5.31M | $11.46M | $13.12M | $5.75M | $4.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.25% | 1.44% | 1.45% | 0.78% | 1.62% | 1.11% | - | 0.74% | 0.70% | 0.69% | 2.00% | 0.98% | 0.50% | 1.08% | 1.12% | 0.47% | 0.42% | 1.00% | 1.00% |
Surmodics's average Quarter SG&A projection for Mar 24 is $18.19M, based on 1 Wall Street analysts, with a range of $14.55M to $21.83M. The forecast indicates a 45.11% rise compared to SRDX last annual SG&A of $12.54M (Dec 23).
Surmodics EPS Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.06 | $0.48 | $2.42 | $-0.55 | $-0.56 | $-1.06 | - | $-0.29 | $-0.30 | $-0.02 | $-0.24 | $0.59 | - | $-0.22 | $0.18 | $0.11 | $0.01 | $0.27 | $0.11 |
| Avg Forecast | $-0.09 | $-0.09 | $-0.09 | $-0.09 | $-0.01 | $-0.03 | $-0.09 | $-0.12 | $-0.29 | $-0.34 | $-0.35 | $-0.33 | $0.16 | $-0.46 | $-0.55 | $-0.63 | $-0.47 | $-0.40 | $-0.36 | $-0.31 | $-0.26 | $-0.18 | $0.56 | $-0.07 | $-0.12 | $0.14 | $-0.14 | $-0.08 | $0.33 | $0.04 |
| High Forecast | $-0.08 | $-0.09 | $-0.09 | $-0.09 | $-0.01 | $-0.03 | $-0.09 | $-0.12 | $-0.29 | $-0.33 | $-0.35 | $-0.32 | $0.18 | $-0.46 | $-0.54 | $-0.62 | $-0.47 | $-0.40 | $-0.36 | $-0.30 | $-0.26 | $-0.18 | $0.56 | $-0.06 | $-0.12 | $0.14 | $-0.14 | $-0.08 | $0.34 | $0.04 |
| Low Forecast | $-0.09 | $-0.09 | $-0.09 | $-0.09 | $-0.01 | $-0.03 | $-0.09 | $-0.12 | $-0.30 | $-0.34 | $-0.35 | $-0.33 | $0.14 | $-0.47 | $-0.56 | $-0.64 | $-0.48 | $-0.40 | $-0.37 | $-0.31 | $-0.27 | $-0.18 | $0.55 | $-0.07 | $-0.12 | $0.14 | $-0.14 | $-0.08 | $0.33 | $0.03 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.17% | 3.05% | -5.26% | 1.00% | 0.89% | 2.23% | - | 0.79% | 0.98% | 0.08% | 1.32% | 1.06% | -0.00% | 1.87% | 1.31% | -0.79% | -0.13% | 0.81% | 3.14% |
According to 2 Wall Street analysts, Surmodics's projected average Quarter EPS for Dec 23 is $-0.33, with a low estimate of $-0.33 and a high estimate of $-0.32. This represents a -167.71% decrease compared to SRDX previous annual EPS of $0.48 (Sep 23).
Surmodics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.16 | $8.50 | 632.76% | Buy |
| INGN | Inogen | $11.33 | $26.00 | 129.48% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| CNMD | CONMED | $75.40 | $101.00 | 33.95% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| ITGR | Integer | $126.78 | $131.00 | 3.33% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
SRDX Forecast FAQ
Is Surmodics a good buy?
Yes, according to 2 Wall Street analysts, Surmodics (SRDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of SRDX's total ratings.
What is SRDX's price target?
Surmodics (SRDX) average price target is $39.5 with a range of $36 to $43, implying a 0.36% from its last price of $39.36. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Surmodics stock go up soon?
According to Wall Street analysts' prediction for SRDX stock, the company can go up by 0.36% (from the last price of $39.36 to the average price target of $39.5), up by 9.25% based on the highest stock price target, and down by -8.54% based on the lowest stock price target.
Can Surmodics stock reach $60?
SRDX's average twelve months analyst stock price target of $39.5 does not support the claim that Surmodics can reach $60 in the near future.
What are Surmodics's analysts' financial forecasts?
Surmodics's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $137.75M (high $139.11M, low $136.89M), average EBITDA is $5.62M (high $5.68M, low $5.59M), average net income is $-3.543M (high $-3.514M, low $-3.588M), average SG&A $46.6M (high $47.06M, low $46.31M), and average EPS is $-0.25 (high $-0.248, low $-0.253). SRDX's analysts financial forecasts for the fiscal year (Sep 2026) are as follows: average revenue is $140.11M (high $141.5M, low $139.24M), average EBITDA is $5.72M (high $5.77M, low $5.68M), average net income is $-4.921M (high $-4.881M, low $-4.984M), average SG&A $47.4M (high $47.87M, low $47.1M), and average EPS is $-0.347 (high $-0.344, low $-0.352).
Did the SRDX's actual financial results beat the analysts' financial forecasts?
Based on Surmodics's last annual report (Sep 2023), the company's revenue was $132.58M, beating the average analysts forecast of $102.54M by 29.30%. Apple's EBITDA was $14.58M, missing the average prediction of $-670K by -2275.17%. The company's net income was $-1.536M, missing the average estimation of $-19.255M by -92.02%. Apple's SG&A was $51.88M, beating the average forecast of $42.48M by 22.14%. Lastly, the company's EPS was $-0.11, missing the average prediction of $-1.479 by -92.56%. In terms of the last quarterly report (Dec 2023), Surmodics's revenue was $30.55M, beating the average analysts' forecast of $29.64M by 3.06%. The company's EBITDA was $-322K, missing the average prediction of $1.21M by -126.62%. Surmodics's net income was $-786K, missing the average estimation of $-4.605M by -82.93%. The company's SG&A was $12.54M, beating the average forecast of $10.03M by 25.02%. Lastly, the company's EPS was $-0.0557, missing the average prediction of $-0.325 by -82.86%